BioStock: Saniona initiates clinical trial in rare disease
Saniona has started the phase IIb clinical trial with Tesomet in patients with the rare disease hypothalamic obesity. Results from the study are expected in the second half of 2023. Saniona is already strengthened by an FDA orphan drug designation as well as promising data from a previous phase II study, and the Q3 report indicates significant market potential.
Read the full article about Saniona at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/